Navigation Links
Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
Date:2/17/2009

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
6. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
7. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
8. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
9. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
10. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
11. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... COSTA MESA, Calif. , July 25, 2014 /PRNewswire-iReach/ ... Peter Nieto as the new Vice President ... industry for over 30 years in a number of ... CROs in the industry. These positions were primarily related ... has obtained over the past 30 years makes him ...
(Date:7/25/2014)... OF SPAIN, Trinidad and Tobago , July ... Division of the Trinidad & Tobago Ministry of ... market, an innovative therapy that significantly increases the cure ... for patients infected with the genotype 1 virus. ... under the trade brand INCIVO®. ...
(Date:7/25/2014)... Group Inc (OTC: SLNX) is pleased to announce that ... the Letter of Intent issued on July 11, 2014 ... Charles R. Shirley , Managing Director ... David Pecoraro and Buzznbrewz.com join SLNX,s team.  ... and developed a tremendous network of contacts who have ...
Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... , , TOKYO ... Daiichi Sankyo Company, Limited (TSE: 4568), announced today that ... for edoxaban, its investigational oral Factor Xa inhibitor. This new ... and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) ...
... , , SOMERSET, N.J. , Feb. ... trials in patients with acute low back pain (ALBP) who ... functionality and reduced disability after three days of treatment, as ... being presented this week at the 26th annual meeting of ...
Cached Medicine Technology:Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 2Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 3Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 4Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 5SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 2SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 3SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 4SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 5
(Date:7/27/2014)... have shown that a powerful drug given at the ... the early risk of rejection, but that it also ... be used after the operation. , The key results ... at the World Transplant Congress in San Francisco today. ... conundrum: the powerful combinations of treatments used to prevent ...
(Date:7/27/2014)... 27, 2014 The report, “Glass ... Market By Raw Material, By Manufacturing Process, By ... & By Geography – Global Trends & Forecast ... Composites market with an analysis and forecast by ... tables and 107 figures spread through 347 slides ...
(Date:7/27/2014)... The inaugural Latino Conservation Action Week ... protecting our environment and getting outdoors. During the week, ... on hiking or camping outings, participate in community events ... permanently protecting our land, water and air. , ... on the environment like the need to protect our ...
(Date:7/27/2014)... constant expansion of companies across the globe has led ... factors that have increased this demand include the application ... learning and development, security and safety, and knowledge sharing ... video market value has crossed $11.21 billion in 2013 ... with a compound annual growth rate (CAGR) of 25.97%. ...
(Date:7/27/2014)... York, NY (PRWEB) July 27, 2014 ... Tea Production industry has fared well, thanks to ... and coffee blends. According to the Coffee Association of ... available), Canadians consume 2.7 cups of coffee per day. ... light on the health benefits of drinking tea on ...
Breaking Medicine News(10 mins):Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... a Healthier Future, WASHINGTON, Oct. 22 ... is launching a,national health campaign to vaccinate more ... than 1.5 million insecticide-treated,mosquito nets to prevent the ... than 1 million African children each year. ...
... The University of Alabama at Birmingham (UAB) Center ... a $3.8 million grant renewal from the U.S. Department ... arthritic and musculoskeletal diseases and their treatments. , The ... in the nation, to continue its often-cited research on ...
... new model of nonprofit fund-raising events and raises ... more than ... and women from,across the country climbed more than 1,000 stairs ... Up to Fight Diabetes,fund-raising challenge. The Step Up event raised ...
... snooze-time, experts say , , SATURDAY, Oct. 20 (HealthDay News) -- ... Sunday in November, you should use that extra hour to ... , Too often, work and family responsibilities take precedence over ... Sleep Disorders Clinic at Stanford University Medical Center in Palo ...
... Inc. (Nasdaq: AMCS ),a leader in radiology and medical image ... results,for the second quarter ended September 30, 2007, before the market ... ), WHEN: ... -- Call begins promptly at 8:30 a.m. (Eastern Time), ...
... 19 Broadband Wireless,International Corporation (Pink Sheets: BBAN) ... discussions with Mr. Kenneth Andam in,connection with HealthPitch, ... to a continuing business relationship,connecting Mr. Andam and ... of good faith negotiations have commenced between BBAN ...
Cached Medicine News:Health News:Government of Madagascar and Coalition of Global Partners Launch Measles and Malaria Prevention Campaign 2Health News:Government of Madagascar and Coalition of Global Partners Launch Measles and Malaria Prevention Campaign 3Health News:Musculoskeletal center wins $3.8 million research grant 2Health News:American Diabetes Association Steps Up to Fight Diabetes 2Health News:American Diabetes Association Steps Up to Fight Diabetes 3Health News:Fall Time Change Could Be Boon for Sleep 2Health News:AMICAS Schedules Third Quarter Earnings Call 2Health News:Broadband Wireless International Corporation Announces the Commencement of Good Faith Talks with HealthPitch 2
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Liquichek Serum Volatiles Control is a bilevel liquid control with assayed values for the most widely measured volatile compounds....
... Urine Control contains a comprehensive ... that monitor tests for general ... hormones. It also contains hCG ... microalbumin at levels suitable for ...
Medicine Products: